Manufacturer of Controlled Substances; Notice of Application, 36482 [E7-12947]

Download as PDF 36482 Federal Register / Vol. 72, No. 127 / Tuesday, July 3, 2007 / Notices CFR 1301.34(b), (c), (d), (e) and (f) are satisfied. DEPARTMENT OF JUSTICE Dated: June 26, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–12941 Filed 7–2–07; 8:45 am] Drug Enforcement Administration BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Importer of Controlled Substances; Notice of Application Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this is notice that on February 2, 2007, Lipomed, Inc., One Broadway, Cambridge, Massachusetts 02142, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedules II: Drug Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 13, 2007, Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066–1742, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II: Drug Schedule Cocaine (9041) ............................. Ecgonine (9180) ........................... II II jlentini on PROD1PC65 with NOTICES The company plans on producing cocaine for sale to its customers, who are final dosage manufacturers. The ecgonine is formed during the manufacturing process for cocaine. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administrator, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537; or any being sent via express mail should be sent to Drug Enforcement Administration, Federal Register Representative (ODL); 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 4, 2007. Dated: June 26, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–12947 Filed 7–2–07; 8:45 am] BILLING CODE 4410–09–P VerDate Aug<31>2005 17:57 Jul 02, 2007 Jkt 211001 Drug Schedule Cathinone (1235) .......................... Methcathinone (1237) .................. N-Ethylamphetamine (1475) ........ Methaqualone (2565) ................... Gamma Hydroxybutyric Acid (2010). Lysergic acid diethylamide (7315) 2,5–Dimethoxy-4-(n)propylthiophenethylamine (7348). Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... Mescaline (7381) .......................... 3,4,5–Trimethoxyamphetamine (7390). 4–Bromo-2,5dimethoxyamphetamine (7391). 4–Bromo-2,5dimethoxyphenethylamine (7392). 4–Methyl-2,5dimethoxyamphetamine (7395). 2,5–Dimethoxyamphetamine (7396). 2,5–Dimethoxy-4ethylamphetamine (7399). 3,4–Methylenedioxyamphetamine (7400). 3,4–Methylenedioxy-Nethylamphetamine (7404). 3,4– Methylenedioxymethamphetamine (7405). 4–Methoxyamphetamine (7411) ... Dimethyltryptamine (7435) ........... Psilocybin (7437) .......................... Psilocyn (7438) ............................. Acetyldihydrocodeine (9051) ........ Dihydromorphine (9145) ............... Heroin (9200) ............................... Normorphine (9313) ..................... Pholcodine (9314) ........................ Tilidine (9750) ............................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Phencyclidine (7471) .................... Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Benzoylecgonine (9180) ............... PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II II II II II II II II II II II Ethylmorphine (9190) ................... Hydrocodone (9193) ..................... Levorphanol (9220) ...................... Meperidine (9230) ........................ Methadone (9250) ........................ Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... Alfentanil (9737) ........................... Fentanyl (9801) ............................ Sufentanil (9740) .......................... Schedule II II II II II II II II II II II II The company plans to import analytical reference standards for distribution to its customers for research and analytical purposes. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedule I or II, which fall under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C 952 (a)(2)(B) may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537; or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than August 2, 2007. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substances in schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C 958(a); 21 U.S.C 823(a); and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied. E:\FR\FM\03JYN1.SGM 03JYN1

Agencies

[Federal Register Volume 72, Number 127 (Tuesday, July 3, 2007)]
[Notices]
[Page 36482]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-12947]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on March 13, 2007, Johnson 
Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West 
Deptford, New Jersey 08066-1742, made application by letter to the Drug 
Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
schedule II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cocaine (9041).............................  II
Ecgonine (9180)............................  II
------------------------------------------------------------------------

    The company plans on producing cocaine for sale to its customers, 
who are final dosage manufacturers. The ecgonine is formed during the 
manufacturing process for cocaine.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administrator, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537; or any being sent via 
express mail should be sent to Drug Enforcement Administration, Federal 
Register Representative (ODL); 2401 Jefferson Davis Highway, 
Alexandria, Virginia 22301; and must be filed no later than September 
4, 2007.

    Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E7-12947 Filed 7-2-07; 8:45 am]
BILLING CODE 4410-09-P